JTC 064
Alternative Names: JTC-064Latest Information Update: 04 Oct 2023
At a glance
- Originator JT Pharmaceuticals
- Developer Akros Pharma; JT Pharmaceuticals
- Class Neuroprotectants
- Mechanism of Action Pyruvate dehydrogenase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurodegenerative disorders
Most Recent Events
- 30 Sep 2022 Phase-I clinical trials in Neurodegenerative disorders in USA (PO) (Akros Pharma pipeline; September 2023)